CoChat

Comparisons of weight changes between sodium‐glucose cotransporter 2 inhibitors treatment and glucagon‐like peptide‐1 analogs treatment in type 2 diabetes patients: A meta‐analysis

Open access
Cai, Xiaoling, Ji, Liwei, Chen, Yifei, Yang, Wenjia, Zhou, Lingli, Han, Xueyao, Zhang, Simin, Ji, Linong · 2017 · Journal of Diabetes Investigation
Cited by 66

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Aims/Introduction: To evaluate the efficacy of weight changes from baseline of the sodium‐glucose cotransporter 2 (SGLT2) inhibitors treatment and glucagon‐like peptide‐1 (GLP‐1) analogs treatment after comparisons with a placebo in type 2 diabetes patients, and the associated factors. Materials and Methods: Studies were searched from when recording began, June 2004, until June 2015, and re‐searched in July 2016, and placebo‐controlled randomized trials in type 2 diabetes patients with a study length of ≥12 weeks were included. Results: A total of 97 randomized controlled trials were included. Compared with a placebo, treatment with SGLT2 inhibitors was associated with a significantly greater decrease in weight change from baseline (weighted mean differences −2.01 kg, 95% confidence interval −2.18 to −1.83 kg, P < 0.001). Compared with a placebo, changes with GLP ‐1 treatment were also associated with a comparable decrease in weight change from baseline (weighted mean differences −1.59 kg, 95% confidence interval −1.86 to −1.32 kg, P < 0.001). Meta‐regression analysis showed that the baseline age, sex, baseline glycated hemoglobin, diabetes duration or baseline body mass index were not associated with the weight change from baseline in SGLT2 inhibitors or in GLP‐1 treatment corrected by placebo. Comparisons of weight changes from baseline corrected by placebo between SGLT2 inhibitors and GLP‐1 treatment showed that the difference was not significant (P > 0.05). Conclusions: According to the present meta‐analysis, treatment with SGLT2 inhibitors and treatment with GLP‐1 analogs led to comparable weight changes from baseline, which are both with significance when compared with placebo treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jdi.12625

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 19

  1. 10.2337/dc12-0413 · DOI · Paper page
  2. 10.3810/pgm.2008.07.1785 · DOI
  3. 10.2337/diacare.20.11.1744 · DOI · Paper page
  4. 10.1007/s13300-012-0013-8 · DOI
  5. 10.2337/diabetes.54.12.3427 · DOI · Paper page
  6. 10.1007/s13300-011-0004-1 · DOI
  7. 10.1111/1753-0407.12196 · DOI
  8. 10.1016/j.diabres.2008.03.018 · DOI
  9. 10.2165/00002018-200730120-00005 · DOI · Paper page
  10. 10.1136/bmj.d410 · DOI
  11. 10.1111/j.1463-1326.2009.01075.x · DOI · Paper page
  12. 10.1111/j.1463-1326.2011.01434.x · DOI · Paper page
  13. 10.2337/dc09-0517 · DOI · Paper page
  14. 10.2337/dc10-0612 · DOI · Paper page
  15. 10.2165/11318680-000000000-00000 · DOI
  16. 10.1111/j.1742-1241.2008.01805.x · DOI · Paper page
  17. 10.1210/jc.2015-1884 · DOI · Paper page
  18. 10.1016/S2213-8587(14)70227-X · DOI · Paper page
  19. Kaur A, 2015, Severe hypercalcemia and hypernatremia in a patient treated with canagliflozin, Endocrinol Diabetes Metab Case Rep, 2015, 150042

Cited by

See all 66

Metadata

Authors
Cai, X., Ji, L., Chen, Y., Yang, W., Zhou, L., Han, X., Zhang, S., & Ji, L.
Venue
Journal of Diabetes Investigation
Publisher
Wiley
Published
2017-03-23
Volume
8
Issue
4
Pages
510-517
ISSN
  • 2040-1116 (ISSN-L)
  • 2040-1124
OpenAlex
W2573636778
Cited by
66
References
17
FWCI
5.01
Type
journal article
Language
en
Open access
gold
Funders
National Natural Science Foundation of China (81000334)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparisons of weight changes between sodium‐glucose cotransporter 2 inhibitors treatment and glucagon‐like peptide‐1 analogs treatment in type 2 diabetes patients: A meta‐analysis. https://app.cochat.ai/papers/10.1111/jdi.12625
The paper
Cai, X., Ji, L., Chen, Y., Yang, W., Zhou, L., Han, X., Zhang, S., & Ji, L. (2017). Comparisons of weight changes between sodium‐glucose cotransporter 2 inhibitors treatment and glucagon‐like peptide‐1 analogs treatment in type 2 diabetes patients: A meta‐analysis. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.12625

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.